Sol-Gel Technologies Debt to Equity Ratio 2016-2025 | SLGL
Current and historical debt to equity ratio values for Sol-Gel Technologies (SLGL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Sol-Gel Technologies debt/equity for the three months ending March 31, 2025 was 0.00.
| Sol-Gel Technologies Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2025-03-31 |
$0.01B |
$0.02B |
0.34 |
| 2024-12-31 |
$0.01B |
$0.03B |
0.24 |
| 2024-09-30 |
$0.01B |
$0.04B |
0.24 |
| 2024-06-30 |
$0.01B |
$0.04B |
0.20 |
| 2024-03-31 |
$0.01B |
$0.03B |
0.22 |
| 2023-12-31 |
$0.01B |
$0.04B |
0.17 |
| 2023-09-30 |
$0.01B |
$0.04B |
0.16 |
| 2023-06-30 |
$0.01B |
$0.05B |
0.14 |
| 2023-03-31 |
$0.01B |
$0.04B |
0.11 |
| 2022-12-31 |
$0.00B |
$0.04B |
0.11 |
| 2022-09-30 |
$0.00B |
$0.05B |
0.08 |
| 2022-06-30 |
$0.01B |
$0.05B |
0.09 |
| 2022-03-31 |
$0.01B |
$0.05B |
0.12 |
| 2021-12-31 |
$0.01B |
$0.06B |
0.25 |
| 2021-09-30 |
$0.01B |
$0.04B |
0.28 |
| 2021-06-30 |
$0.01B |
$0.04B |
0.18 |
| 2021-03-31 |
$0.01B |
$0.05B |
0.14 |
| 2020-12-31 |
$0.01B |
$0.05B |
0.16 |
| 2020-09-30 |
$0.01B |
$0.06B |
0.16 |
| 2020-06-30 |
$0.01B |
$0.07B |
0.14 |
| 2020-03-31 |
$0.01B |
$0.07B |
0.14 |
| 2019-12-31 |
$0.01B |
$0.05B |
0.17 |
| 2019-09-30 |
$0.01B |
$0.06B |
0.16 |
| 2019-06-30 |
$0.01B |
$0.06B |
0.16 |
| 2019-03-31 |
$0.01B |
$0.06B |
0.15 |
| 2018-12-31 |
$0.01B |
$0.06B |
0.09 |
| 2018-09-30 |
$0.01B |
$0.08B |
0.08 |
| 2018-06-30 |
$0.01B |
$0.08B |
0.06 |
| 2018-03-31 |
$0.00B |
$0.09B |
0.03 |
| 2017-12-31 |
$0.00B |
|
0.00 |
| 2017-09-30 |
$0.07B |
$-0.05B |
-1.47 |
| 2017-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-12-31 |
$0.04B |
$-0.03B |
-1.35 |
| 2015-12-31 |
$0.02B |
$-0.01B |
-1.72 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.021B |
$0.012B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
